Showing results (51-60 of 58) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
JHEP Reports : Innovation in Hepatology|March 13, 2023
Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cellsAbhishek Aggarwal, Pamela M Odorizzi, Jens Brodbeck, et al.International Journal of Computer Assisted Radiology and Surgery|April 24, 2026
Shift happens: a fairness-oriented framework for medical classification under hidden biasMinh Nguyen Nhat To, Diane Kim, Mohamed Harmanani, et al.Journal of Viral Hepatitis|June 4, 2026
Genotypes of Hepatitis B and D Viruses Among Patients With Hepatitis D in the United StatesAndrew Lopez, Harish Gopalakrishna, Silvia Chang, et al.Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes|August 6, 2025
Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLDMitchell P Wilson, Gavin Low, Abdel-Aziz Shaheen, et al.JHEP Reports : Innovation in Hepatology|November 6, 2023
Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDVRoberto Mateo, Simin Xu, Alex Shornikov, et al.Proceedings of the National Academy of Sciences of the United States of America|October 8, 2020
Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerasesMichael K Lo, César G Albariño, Jason K Perry, et al.Antimicrobial Agents and Chemotherapy|July 25, 2018
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B InfectionAndrea L Cathcart, Henry Lik-Yuen Chan, Neeru Bhardwaj, et al.Journal of Hepatology|April 29, 2023
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis deltaJulius Hollnberger, Yang Liu, Simin Xu, et al.Pageof 6